重组人白细胞介素-11药物利用评价标准建立与使用合理性分析  

Establishment and rationality analysis of evaluation criteria for drug utilization of recombinant human interleukin-11

作　　者：杨凌妍 刘秀梅 沈曦凤 张进华 谌赟[4] Yang Lingyan;Liu Xiumei;Shen Xifeng;Zhang Jinhua;Chen Yun(Department of Clinical Pharmacy,Second People′s Hospital of Changde,Changde,Hunan 415100,China;Department of Pharmacy,Fifth Clinical Medical College,Henan University of Traditional Chinese Medicine(Zhengzhou People′s Hospital),Zhengzhou,Henan 450000,China;Department of Pharmacy,Fujian Maternal and Child Health Hospital,Fuzhou,Fujian350000,China;Department of Pharmacy,Hunan Cancer Hospital,Changsha,Hunan 410000,China)

机构地区：[1]常德市第二人民医院临床药学室,湖南常德415100 [2]河南中医药大学第五临床医学院(郑州人民医院)药学部,河南郑州450000 [3]福建省妇幼保健院药剂科,福建福州350000 [4]湖南省肿瘤医院药学部,湖南长沙410000

出　　处：《中国药物与临床》2023年第3期143-149,共7页Chinese Remedies & Clinics

基　　金：湖南省科卫联合基金(2022JJ70102)。

摘　　要：目的建立重组人白细胞介素-11(rhIL-11)药物利用评价标准(DUE),找出临床不合理使用相关问题,为临床合理使用rhIL-11提供参考,为临床药师处方点评提供依据。方法以rhIL-11药品说明书为基础,参考相关指南、专家共识及循证医学证据,通过各专业专家咨询法制订rhIL-11的DUE,通过美康合理用药监测系统(PASS)抽取湖南省常德市第二人民医院2021年1月至2022年6月使用rhIL-11的出院患者100例进行合理性评价,具体包括适应证、禁忌证、用法用量、给药停药时机、疗程、药物疗效监护、不良反应监测、处置及药物转换、临床结局等。结果使用rhIL-11的100例中,用药完全合理的患者3例(3%),用药不合理的患者97例(97%)。不合理应用常见于适应证不适宜(9例,9%)、用法用量不适宜(33例,33%)、溶媒不合理(93例,93%)、用药疗程不合理(63例,63%)、给药时机不合理2例(2%)。结论建立的rhIL-11 DUE具有较强的科学性、实用性和可行性,该院rhIL-11在临床应用中尚存在一些问题,临床药师需加大管理力度,促进rhIL-11的临床合理应用。Objective To establish the criteria for drug use evaluation(DUE)of recombinant human in-terleukin-11(rhIL-11)and to find out the problems related to clinical irrational use,to provide reference for clinical rational use of rhIL-11,and to provide the basis for clinical pharmacists′prescription review.Methods Based on the drug insert of recombinant human interleukin-11,and with reference to relevant guidelines,expert consensus and evidence-based medical evidence,the evaluation criteria for rhIL-11 drug utilization were formulated through professional expert consultation.One hundred patients discharged randomly with PASS from Second People′s Hospital of Changde,using rhIL-11 from January 2021 to June 2022 were rationally evaluated,including indica-tions,contraindications,usage and dosage,administration time of drug withdrawal,course of treatment,monitoring of drug efficacy,adverse monitoring reactions,monitoring treatment and drug switching,and clinical outcomes,etc.Results Of the 100 cases in which rhIL-11 was used,3 patients(3%)used the drug completely rationally and 97 patients(97%)used the drug irrationally.Irrational application was commonly found in inappropriate indications(9%),inappropriate usage and dosage(33%),unreasonable solvent(93%),unreasonable duration of medication(63%),and administration timing unreasonable(2%).Conclusion The established DUE of recombinant human interleukin-11 has strong scientificity,practicability and feasibility.The results show that there are still some prob-lems in the clinical application of rhIL-11 in this hospital.Clinical pharmacists need to increase management ef-forts to promote the rational clinical application of rhIL-11.

关 键 词：白细胞介素-11 药物利用评审 药学服务 

分 类 号：R973[医药卫生—药品]